Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Jun;75(6):e14124.
doi: 10.1111/ijcp.14124. Epub 2021 Mar 13.

Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial

Masoud Nouri-Vaskeh  1   2 , Niusha Kalami  3 , Ramin Zand  4 , Zahra Soroureddin  5 , Mojtaba Varshochi  6 , Khalil Ansarin  3 , Haleh Rezaee  6 , Ali Taghizadieh  3 , Armin Sadeghi  3 , Masoud Ahangari Maleki  3 , Azam Esmailnajad  3 , Parviz Saleh  7 , Mehdi Haghdoost  6 , Mehdi Maleki  8 , Akbar Sharifi  3
Affiliations
Randomized Controlled Trial

Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial

Masoud Nouri-Vaskeh et al. Int J Clin Pract. 2021 Jun.

Abstract

Background: Controversy exists regarding the drug selection in hypertension (HTN) management in patients with COVID-19. This study aimed to compare the effects of losartan and amlodipine in patients with primary HTN and COVID-19.

Methods: In this randomised clinical trial, hospitalised patients with COVID-19 and primary HTN were enrolled in the study. One arm received losartan, 25 mg, twice a day and the other arm received amlodipine, 5 mg per day for 2 weeks. The main outcomes were compare 30-day mortality rate and length of hospital stay.

Results: The mean age of patients treated with losartan (N = 41) and amlodipine (N = 39) was 67.3 ± 14.8 and 60.1 ± 17.3 years, respectively (P value = .068). The length of hospital stay in losartan and amlodipine groups was 4.57 ± 2.59 and 7.30 ± 8.70 days, respectively (P value = .085). Also, the length of ICU admission in losartan and amlodipine group was 7.13 ± 5.99 and 7.15 ± 9.95 days, respectively (P value = .994). The 30-day mortality was two and five patients in losartan and amlodipine groups, respectively (P value = .241).

Conclusions: There was no priority in losartan or amlodipine administration in COVID-19 patients with primary HTN in decreasing mortality rate, hospital and ICU length stay. Further studies need to clarify the first-line anti-HTN medications in COVID-19.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Study flow diagram
See this image and copyright information in PMC

Comment in

References

    1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708‐1720. - PMC - PubMed
    1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054‐1062. - PMC - PubMed
    1. Nouri‐Vaskeh M, Alizadeh L. Fecal transmission in COVID‐19: a potential shedding route. J Med Virol. 2020;92:1731‐1732. - PMC - PubMed
    1. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS‐CoV‐2: a systematic review and meta‐analysis. Int J Infect Dis. 2020;94:91‐95. - PMC - PubMed
    1. Nouri‐Vaskeh M, Khalili N, Sharifi A, et al. Clinical characteristics of fatal cases of COVID‐19 in Tabriz, Iran: an analysis of 111 patients. Adv J Emerg Med. 2020;5:e12.

Publication types